PEAR Therapeutics
-
Devices & Diagnostics, BioPharma
Rigorous Data Are Key to Convince Payers, Investors in the World of Digital Therapeutics
Pear Therapeutics was once regarded as a digital therapeutics pioneer, but its spiral into bankruptcy has the industry searching for the best path forward. While some favor going direct to consumers, others say the solution is in generating more robust clinical trial data to persuade hesitant payers.
-
MedCity Influencers, Health Tech
What Pear Therapeutics’ Bankruptcy Has Left the DTX Industry to Ponder
One of the fastest-growing frontiers of healthcare is Digital Therapeutics (DTx), which utilizes clinically tested […]
-
Payer’s Place: Dawn Maroney
Dawn Maroney, President, Markets of Alignment Health and CEO of Alignment Health Plan, to discuss how they are using technology to provide better service and care to consumers.
-
Devices & Diagnostics, BioPharma
Pear Therapeutics Files for Bankruptcy and Plans for Asset Auction in May
Pear Therapeutics’ Chapter 11 bankruptcy filing follows three corporate restructurings and the inability to secure additional financing to support commercialization of its FDA-cleared prescription digital therapeutics. An auction of Pear’s assets is expected to happen in early May.
-
Pear Therapeutics’ Cuts Are Not Enough; ‘Strategic Alternatives’ Among Next Steps
Pear Therapeutics isn’t meeting the commercialization goals for its prescription digital therapeutics, so it’s now seeking strategic alternatives for the business. Prospective buyers can pick up Pear’s FDA-cleared products for substance use disorder, opioid use disorder, and insomnia.
-
Devices & Diagnostics, BioPharma
Pear Therapeutics pares down its plans as restructuring cuts 9% of workforce
Pear Therapeutics is implementing a corporate restructuring projected to save about $28 million. The goal is to extend its available cash as the company presses on with commercialization efforts for its digital therapeutics.
-
Pear’s digital therapeutic for alcohol use disorder gets breakthrough designation
The company got a breakthrough device designation for its app-based program for alcohol use disorder, reset-A. Pear currently has FDA-cleared digital therapeutics to address opioid use and substance use disorders.
-
Pear Therapeutics plans to go public in $1.6B SPAC deal
Digital therapeutics startup Pear Therapeutics struck a deal to go public through a blank-check acquisition that would value the company at $1.6B. But it still faces big challenges in selling its app-based treatments.
-
‘Smart pill’ startup etectRx strikes partnership with Pear Therapeutics
EtectRx, which makes wireless sensors embedded in medications, struck a partner with Pear Therapeutics. The companies hope to build products together combining medication adherence data with digital therapeutics.
-
Pear Therapeutics raises $80M in push for reimbursement
SoftBank’s second Vision Fund led the recent funding round. Pear plans to use it to accelerate reimbursement coverage for its three FDA-cleared products.
-
Applying Remote Patient Monitoring to Surgery Prep and Recovery, Oncology and Women’s Health
Join us to learn about the latest trends in remote monitoring and how to extend its benefits beyond chronic conditions to more patients – all while using fewer staff resources.
-
Pear rolls out digital therapeutic for insomnia
After receiving FDA clearance in March, Pear began marketing its prescription digital therapeutic for insomnia. It’s available by prescription only.
-
Digital therapeutics make strides during pandemic, but still face adoption hurdles
Lightened regulations and cancelled appointments have led to an uptick in the number of patients using digital therapeutics. But companies still face many of the same obstacles as before, including securing coverage and reimbursement from insurers.
-
FDA OKs digital health tools for use during pandemic
Recent moves by the Food and Drug Administration have given digital health companies a big boost during the Covid-19 pandemic. The FDA gave Livongo an emergency use authorization to allow its blood glucose monitors to be used in hospitals, and has loosened requirements around the use of digital tools for mental health.
-
Pear gets FDA clearance for insomnia therapeutic
Pear Therapeutics received market authorization from the FDA for its insomnia digital therapeutic, Somryst. It is Pear’s third product to receive FDA clearance, and the first product to be reviewed under the FDA’s new software precertification pilot program.
-
Health IT, Startups, Health Tech
Healthcare startups saw more deals, fewer dollars in 2019
Healthcare startups saw smaller amounts of investment after a record-breaking 2018, according to a report from Silicon Valley Bank. Despite the dip in funding, 2019 saw more deals overall, led by increased investment into healthcare technology companies.
-
Startups, Devices & Diagnostics, Health Tech
Digital health, digital therapeutics, digital medicines – what’s in a name?
Digital health companies faced bad news going into 2020, from job cuts to dissolving pharma partnerships. But these struggles are part of an industry that is finding its identity in a crowded healthcare market.
Promoted
Payer’s Place: Dr. Anil Singh
Dr. Anil Singh shares his insights into the strategies employed by the organization to identify the most effective digital solutions for their members.
Promoted
Discover the Next-Gen Platform for Integrated Collaborative Care
Beyond EHRs and digital front doors, reducing the gaps in patient care journeys.
